Vibecotamab

维克妥单抗

Report date: 2026/05/23 20:00:57

Base Information

Drug NameVibecotamab
Drug Alias NameXmAb-14045
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionInterleukin-3 receptor subunit alpha inhibitorsCD3 T-cell engagers
TargetsT cell surface glycoprotein CD3Interleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesXencor Inc
China Registration ClassN/A

Develop Information

Active CompaniesXencor IncNovartis Pharma Ag
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmLeukemia, Myeloid, AcuteLeukemia, Myeloid +[4] 
Inactive IndicationsMyelodysplastic Syndromes

Other Information

ATC CodeN/A
Related LinksN/A